{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:08:35Z","timestamp":1779253715834,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["UID\/00100\/2013"],"award-info":[{"award-number":["UID\/00100\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centro de Qu\u00edmica Estrutural","award":["UID\/04138\/2013"],"award-info":[{"award-number":["UID\/04138\/2013"]}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["SAICTPAC\/0019\/2015"],"award-info":[{"award-number":["SAICTPAC\/0019\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["RNEM LISBOA-01-0145-FEDER-402-022125"],"award-info":[{"award-number":["RNEM LISBOA-01-0145-FEDER-402-022125"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ejmech.2019.03.048","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T12:17:52Z","timestamp":1553257072000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability"],"prefix":"10.1016","volume":"172","author":[{"given":"Cl\u00e1udia","family":"Braga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana R.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Concei\u00e7\u00e3o","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-4962","authenticated-orcid":false,"given":"M.","family":"Matilde Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-9852","authenticated-orcid":false,"given":"Rui","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora","family":"Brites","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8110-2740","authenticated-orcid":false,"given":"Maria J.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.03.048_bib1","first-page":"7","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2019.03.048_bib2","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/nov297","article-title":"American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2019.03.048_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"European organisation for Research and treatment of cancer brain tumor and radiotherapy groups, national cancer Institute of Canada clinical trials group, radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.03.048_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.5-2-144","article-title":"Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma","volume":"5","author":"Agarwala","year":"2000","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2019.03.048_bib5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/ph7070797","article-title":"The medicinal chemistry of imidazotetrazine prodrugs","volume":"7","author":"Moody","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejmech.2019.03.048_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.03.048_bib7","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","article-title":"Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results","volume":"21","author":"Berendsen","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2019.03.048_bib8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A\u00a0phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2019.03.048_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","article-title":"Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation","volume":"107","author":"Van Nifterik","year":"2012","journal-title":"J.\u00a0Neuro Oncol."},{"key":"10.1016\/j.ejmech.2019.03.048_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/acschemneuro.6b00169","article-title":"Targeting gliomas: can a new alkylating hybrid compound make a difference?","volume":"8","author":"Pinheiro","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2019.03.048_bib11","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1139\/v77-240","article-title":"Open-chain nitrogen compounds. Part II. Preparation, characterization, and degradation of 1(3)-Aryl-3(1)-methyltriazenes; the effect of substituents on the reaction of diazonium salts with methylamine","volume":"55","author":"Ahern","year":"1977","journal-title":"Can. J. Chem."},{"key":"10.1016\/j.ejmech.2019.03.048_bib12","first-page":"320","article-title":"Synthesis of 1-aryl-3-methyltriazenes by base-promoted decomposition of 1-aryl-3-hydroxymethyl-3-methyltriazenes","author":"Cheng","year":"1983","journal-title":"J.\u00a0Chem. Res."},{"key":"10.1016\/j.ejmech.2019.03.048_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of drug like properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2019.03.048_bib14","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/acschembio.8b00864","article-title":"Tunable stability of imidazotetrazines leads to a potent compound for glioblastoma","volume":"13","author":"Svec","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.03.048_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-1-62703-640-5_2","article-title":"Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology","volume":"1078","author":"Kovalevich","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.03.048_bib16","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1016\/j.biomaterials.2012.02.029","article-title":"Biophysical control of invasive tumor cell behavior by extracellular matrix microarchitecture","volume":"33","author":"Carey","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2019.03.048_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22681-3","article-title":"The mode and dynamics of glioblastoma cell invasion into a decellularized tissue-derived extracellular matrix-based three-dimensional tumor model","volume":"8","author":"Koh","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.03.048_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3892\/ijmm.2014.1795","article-title":"Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms","volume":"34","author":"Abaza","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2019.03.048_bib19","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.lfs.2005.09.047","article-title":"Structure\u2013activity relationship between carboxylic acids and T cell cycle blockade","volume":"78","author":"Gilbert","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2019.03.048_bib20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.ejmech.2008.06.022","article-title":"Towards an efficient prodrug of the alkylating metabolite monomethyltriazene: synthesis and stability of N-acylamino acid derivatives of triazenes","volume":"44","author":"Perry","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.048_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1021\/tx9500742","article-title":"Base sequence selectivity in the alkylation of DNA by 1,3-Dialkyl-3-acyltriazenes","volume":"9","author":"Kroeger Smith","year":"1996","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2019.03.048_bib22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/carcin\/9.4.669","article-title":"DNA sequence specificity of guanine N7-alkylations for a series of structurally related triazenes","volume":"9","author":"Hartley","year":"1988","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2019.03.048_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2013.09.040","article-title":"Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines","volume":"70","author":"Monteiro","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.048_bib24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jps.2600700815","article-title":"Influence of serum albumins on decomposition rates of para-substituted 1-phenyl-3-methyltriazenes and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide in near physiological conditions","volume":"70","author":"Delben","year":"1981","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ejmech.2019.03.048_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1039\/p29910000081","article-title":"Triazene drug metabolites. Part 10. Metal-ion catalysed decomposition of monoalkyltriazenes in ethanol solutions","volume":"2","author":"Iley","year":"1991","journal-title":"J.\u00a0Chem. Soc. Perkin Trans."},{"key":"10.1016\/j.ejmech.2019.03.048_bib26","series-title":"Biology Data Book","year":"1974"},{"key":"10.1016\/j.ejmech.2019.03.048_bib27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1349-7006.2006.00208.x","article-title":"Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy","volume":"97","author":"Szatm\u00e1ri","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2019.03.048_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/scd.2007.0133","article-title":"Persistence of CD133 + cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties","volume":"17","author":"Wu","year":"2008","journal-title":"Stem Cell. Dev."},{"key":"10.1016\/j.ejmech.2019.03.048_bib29","doi-asserted-by":"crossref","first-page":"41443","DOI":"10.1074\/jbc.M110.141390","article-title":"The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a \u03b2-Secretase-dependent pathway","volume":"285","author":"Belyaev","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.03.048_bib30","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1021\/jm200146u","article-title":"Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors","volume":"54","author":"Varasi","year":"2011","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419302715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419302715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:51:38Z","timestamp":1759326698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419302715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"alternative-id":["S0223523419302715"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.03.048","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.03.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}